Sinclair Pharma PLC (LSE: SPH) announced the US launch of its treatment for seborrheic dermatitis by Promius Pharma, the dermatology division of Dr Reddy’s Laboratories Inc.
Sinclair licensed the exclusive rights for the US of its seborrheic dermatitis product, Sebclair, to Dr Reddy's in September 2007. Dr Reddy's is marketing the product under the brand name of Promiseb Cream.
Promiseb / Sebclair Cream is a non-steroidal, prescription only cream for the treatment of seborrheic dermatitis, which has demonstrated both anti-inflammatory and antifungal properties. The condition is a skin disorder affecting the scalp, face, and trunk causing scaly, flaky, itchy, red skin.
Sinclair will receive royalty payments based on the net sales of Promiseb.
Sebclair cream is registered in the EU and has so far been launched in France, Italy and Spain through Sinclair's own operations.
Sinclair chief executive Michael Flynn said: "The launch of Promiseb in the United States further expands the presence of Sinclair products in the US market, bringing the total to seven products now sold in the US ahead of the planned launch of our flagship product, Decapinol, later this financial year.”